We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+10.98%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.21B
AUM Growth
+$34.2M
(+2.9%)
Cap. Flow
+$11.4M
Cap. Flow
% of AUM
0.94%
Top 10 Holdings %
Top 10 Hldgs %
87.78%
Holding
31
New
2
Increased
12
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
STAAR Surgical
STAA
|
+$7M |
| 2 |
Gossamer Bio
GOSS
|
+$6.56M |
| 3 |
NovoCure
NVCR
|
+$2.62M |
| 4 |
Relmada Therapeutics
RLMD
|
+$1.87M |
| 5 |
eHealth
EHTH
|
+$1.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$5.68M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
+$4.25M |
| 3 |
ALIM
Alimera Sciences
ALIM
|
+$544K |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$418K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.91% |
| 2 | Financials | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Mirum Pharmaceuticals
MIRM
$6.04B
| $1.55M | 0.13% |
64,700
| – | – |
|
|
27
Relmada Therapeutics
RLMD
$503M
| $1.23M | 0.1% |
+542,100
| New | +$1.87M |
|
28
Tactile Systems Technology
TCMD
$555M
| $445K | 0.04% |
27,100
| – | – |
|
|
PKBO
29
DELISTED
Peak Bio, Inc. Common Stock
PKBO
| $314K | 0.03% |
497,528
| – | – |
|
30
UroGen Pharma
URGN
$2.39B
| $226K | 0.02% |
24,500
| – | – |
|
|
ALIM
31
DELISTED
Alimera Sciences
ALIM
| – | – |
-200,919
| Closed | -$544K |
|
Similar funds
AG
BL
PIM
ACA
HCM
ACM
DC
FAM
Palo Alto Investors's Q1 2023 Portfolio in Review
As of Q1 2023, Palo Alto Investors held 31 positions worth $1.21B, up 2.9% from $1.17B the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Palo Alto Investors's Q1 2023 filing shows 2 new, 12 increased, 3 reduced and 1 closed positions. Its largest new stake was NovoCure: 32,790 shares worth $1.97M. The largest sale was BioMarin Pharmaceuticals, an estimated $5.68M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.
- Palo Alto Investors's largest Q1 2023 buy was NovoCure: 32,790 shares worth $1.97M.
- Palo Alto Investors added most to STAAR Surgical in Q1 2023, an estimated $7M increase.
- Palo Alto Investors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $5.68M.
- Palo Alto Investors fully exited Alimera Sciences in Q1 2023, selling an estimated $544K.
- Palo Alto Investors's ten largest holdings make up 88% of its $1.21B portfolio in Q1 2023.
- Palo Alto Investors opened 2 new positions and closed 1 in Q1 2023.
- Palo Alto Investors's portfolio value rose 2.9% quarter-over-quarter to $1.21B.
Based on Palo Alto Investors's 13F filing for Q1 2023, filed 15 May 2023.